PA
MATV icon

PharVision Advisers’s Mativ Holdings MATV Stock Holding History

PharVision Advisers’s Portfolio MATV Stock Details MATV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,409
Closed -$248K – 420
2025
Q4 		$248K Buy
20,409
+9,198
+82% +$108K 0.13% 395
2025
Q3 		$127K Buy
+11,211
New +$111K 0.07% 594

Other funds holding MATV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PharVision Advisers's MATV Position: Q1 2026 in Review

PharVision Advisers sold out of Mativ Holdings (MATV) in Q1 2026, closing a stake of 20,409 shares — an estimated $248K sold.

PharVision Advisers first reported a position in MATV in Q3 2025 and held it in 2 quarters. The position peaked at $248K in Q4 2025. 198 funds tracked by Wall St. Rank hold MATV as of Q1 2026.

  • PharVision Advisers reported no remaining Mativ Holdings position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 20,409 Mativ Holdings shares in Q1 2026, an estimated $248K.
  • PharVision Advisers first reported a position in Mativ Holdings in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Mativ Holdings position peaked at $248K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Mativ Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.